Zachary Owen
Zachary Owen has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Clive Smith
2 shared publications- Jonathan A. G. Cox
College of Health and Life Sciences, Aston University, Aston Triangle, Birmingham, UK
2 shared publications Xin Liu
2 shared publications- Adam Nelson
Rosalind Franklin Institute, Harwell Campus, Didcot, Oxfordshire, OX11 0QX, UK.
1 shared publication Antonia Molloy
1 shared publication- Antonia Molloy
School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
1 shared publication
Latest Publications
- Open Access
- 11 November 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (11) , 2330
Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery
Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen Mycobacterium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models that capably mimic all physiological conditions of the infection, and high-throughput drug screening platforms. Microfluidic-based techniques provide single-cell analysis which reduces experimental time and the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review outlines the field of microfluidics and discusses the use of this novel technique so far in M. tuberculosis diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.
- 11 November 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (11) , 2330
Open AccessMicrofluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery
Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen Mycobacterium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models that capably mimic all physiological conditions of the infection, and high-throughput drug screening platforms. Microfluidic-based techniques provide single-cell analysis which reduces experimental time and the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review outlines the field of microfluidics and discusses the use of this novel technique so far in M. tuberculosis diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.
- Open Access
- 29 September 2021
- Published by MDPI AG in Preprints.org
Microfluidics as a Novel Technique for Tuberculosis: From Di-agnostics to Drug Discovery
Tuberculosis (TB) remains a global healthcare crisis with an estimated 10 million new cases and 1.4 million deaths per year TB is caused by infection with the major human pathogen Mycobacte-rium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models which capably mimic all physiological condi-tions of the infection, and high-throughput drug screening platforms. Microfluidic-based tech-niques provide single-cell analysis which reduces experimental time, the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review out-lines the field of microfluidics and discusses the use of this novel technique so far in M. tuberculo-sis diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.
- 29 September 2021
- Published by MDPI AG in Preprints.org
Open AccessMicrofluidics as a Novel Technique for Tuberculosis: From Di-agnostics to Drug Discovery
Tuberculosis (TB) remains a global healthcare crisis with an estimated 10 million new cases and 1.4 million deaths per year TB is caused by infection with the major human pathogen Mycobacte-rium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models which capably mimic all physiological condi-tions of the infection, and high-throughput drug screening platforms. Microfluidic-based tech-niques provide single-cell analysis which reduces experimental time, the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review out-lines the field of microfluidics and discusses the use of this novel technique so far in M. tuberculo-sis diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.
- Open Access
- 1 April 2020
- Published by Elsevier in SLAS Technology
- Vol. 25 (2) , 177-189
Cyto-Mine: An Integrated, Picodroplet System for High-Throughput Single-Cell Analysis, Sorting, Dispensing, and Monoclonality Assurance
- 1 April 2020
- Published by Elsevier in SLAS Technology
- Vol. 25 (2) , 177-189
Open AccessCyto-Mine: An Integrated, Picodroplet System for High-Throughput Single-Cell Analysis, Sorting, Dispensing, and Monoclonality Assurance
- Open Access
- 5 May 2016
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 52 (45) , 7209-7212
A divergent synthetic approach to diverse molecular scaffolds: assessment of lead-likeness using LLAMA, an open-access computational tool
LLAMA was used to assess the lead-likeness of scaffolds prepared via complementary cyclisations of hex-2-ene-1,6-diamine derivatives.
- 5 May 2016
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 52 (45) , 7209-7212
Open AccessA divergent synthetic approach to diverse molecular scaffolds: assessment of lead-likeness using LLAMA, an open-access computational tool
LLAMA was used to assess the lead-likeness of scaffolds prepared via complementary cyclisations of hex-2-ene-1,6-diamine derivatives.